Claims for Patent: 10,064,921

Summary for Patent: 10,064,921

Title:	Botulinum toxin treatments of neurological and neuropsychiatric disorders
Abstract:	Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
Inventor(s):	Blumenfeld; Andrew M. (Del Mar, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	15/447,770
Patent Claims:	1. A method for treating a post-traumatic stress disorder in a patient in need thereof, comprising directly administering a botulinum toxin to a trigeminal nerve of the patient, thereby treating the post-traumatic stress disorder. 2. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A. 3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type B. 4. The method of claim 1, wherein the method of local administration is injection. 5. The method of claim 1, wherein the administering is by non-intramuscular injection. 6. The method of claim 1, wherein the administering is subdermal, intradermal or transdermal. 7. The method of claim 1, wherein the trigeminal nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve. 8. A method for reducing the occurrence of a symptom of post-traumatic stress disorder in a patient with post-traumatic stress disorder, the method comprising locally administering a therapeutically effective amount of a botulinum toxin to a trigeminal sensory nerve or to the vicinity of a trigeminal sensory nerve of the patient, thereby reducing the occurrence of a symptom of post-traumatic stress disorder, wherein the administering is non-intramuscular. 9. The method of claim 8, wherein the botulinum toxin is botulinum toxin type A. 10. The method of claim 8, wherein the botulinum toxin is botulinum toxin type B. 11. The method of claim 8, wherein the method of local administration is injection. 12. The method of claim 8, wherein the administering is by subdermal, intradermal or transdermal. 13. The method of claim 8, wherein the administering is subdermal. 14. The method of claim 8, wherein the therapeutically effective amount of the botulinum toxin administered is between about 1 unit and about 3,000 units. 15. The method of claim 8, wherein the trigeminal sensory nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve.

Details for Patent 10,064,921

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 08, 2000		2023-10-29